On Jan. 7, 2021, Oragenics announced entering into a material transfer agreement with Adjuvance Technologies for use of the adjuvant TQL1055 in the Companyﾒs Terra CoV-2 vaccine against COVID-19.

djuvants are added to vaccines to enhance their immunogenicity. TQL1055 is a novel, rationally designed semi-synthetic analogue of the saponin adjuvant QS-21 with improved attributes including stability and manufacturing efficiency.